Fundz

WhiteLab Genomics secures $26M Series B led by AVP to expand AI-designed gene delivery assets and bio-assets portfolio.

PRIVATEOct 06, 2026

Amount Raised

$26 Million

Round Type

Series B

BiotechnologyGeneticsTherapeutics

Investors

Omnes CapitalBlast.ClubYaday HealthAvpDebiopharm Innovation Fund

Description

WhiteLab Genomics, a genomic medicine company, closed a $26M Series B funding round led by AVP, with participation from new investors Yaday Health and Blast Club, as well as existing shareholders Omnes Capital and Debiopharm Innovation Fund. The funding will support the validation of WhiteLab's computational gene delivery designs in living systems and expand its portfolio of bio-assets. WhiteLab uses its ALFRED AI platform to design and optimize gene delivery components including AAVs, lipid nanoparticles, and synthetic promoters for gene therapy applications. The company focuses on building and licensing validated enabling technologies rather than developing complete medicines independently.

Quick answer

WhiteLab Genomics raised $26 Million in a Series B round, dated October 6, 2026. Investors: Omnes Capital, Blast.Club, Yaday Health, Avp and Debiopharm Innovation Fund.

How much did WhiteLab Genomics raise?
WhiteLab Genomics raised $26 Million in a Series B round on October 6, 2026.
Who invested in WhiteLab Genomics?
Omnes Capital, Blast.Club, Yaday Health, Avp and Debiopharm Innovation Fund are named as investors in this round.
What does WhiteLab Genomics do?
WhiteLab Genomics is building a portfolio of AI-designed gene delivery assets and regulatory components for genomic medicines.

Source: Fundz verified event record.

Who else raised in Genetics and Therapeutics around the same time

Companies in the same sectors as WhiteLab Genomics that raised within 45 days of this round, from Fundz verified event records.

  • VolitionRx raised $2.4M (Convertible Note) on October 27, 2026.
  • Estuary Biotherapeutics raised $93M (Series A) on October 16, 2026.
  • seragy holding GmbH raised $13M on October 14, 2026.
  • Aptadir Therapeutics raised $45M (Seed) on September 29, 2026.
  • Typewriter Therapeutics raised $56M (Series A) on September 2, 2026.
  • Vitri Vax raised $87M (Series C) on November 18, 2026.

Who to call at WhiteLab Genomics, and when

A new round usually means WhiteLab Genomics is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day WhiteLab Genomics raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at WhiteLab Genomics, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at WhiteLab Genomics. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

WhiteLab Genomics

About

WhiteLab Genomics is building a portfolio of AI-designed gene delivery assets and regulatory components for genomic medicines. The company uses its ALFRED platform to design and optimize delivery vectors (like AAVs and lipid nanoparticles) and synthetic promoters, which are then experimentally validated. WhiteLab owns and licenses these validated bio-assets while also partnering with biopharma companies for co-development programs. The company's work spans adeno-associated viruses, nonviral delivery technologies, and synthetic gene expression control elements.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment WhiteLab Genomics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Predictive Intelligence
Strategic

ML-powered predictions for WhiteLab Genomics's next move

See what Strategic adds

Funding Insights

What this usually means
Timeline to next round
Series B companies typically work for 15-20 months before raising new capital
Growth expectations
Series B companies are expected to scale rapidly and expand market reach

WhiteLab Genomics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.